Key result
Severe kidney impairment before TAVI is linked to ~207% higher one-year mortality versus eGFR ≥60.
Why the study?
Contemporary data on the prognostic importance of pre-TAVI kidney function are sparse, leaving uncertainty about which patients derive limited benefit from TAVI.
Does pre-procedural kidney impairment increase one-year mortality and hospitalization burden in patients undergoing TAVI?
Cohort (n=6,409)
Yes
Does pre-procedural kidney impairment increase one-year mortality and hospitalization burden in patients undergoing TAVI?
Hazard Ratio: 3.07 (95% CI 2.32–4.08)
Absolute Event Rate: 19.6% vs 5.6%
p-value: p=<0.0001
Pre-procedural kidney impairment is associated with a stepwise increase in one-year mortality and hospitalization burden following TAVI.
Severe pre-TAVI kidney impairment signals high one-year mortality risk; leaves open whether renal optimization improves outcomes.
Background Prognosis after transcatheter aortic valve implantation (TAVI) keeps improving, yet some high-risk groups persist with chronic kidney disease being one. Contemporary data on the prognostic importance of pre-TAVI kidney function are sparse, leaving uncertainty regarding which patients derive limited benefit from TAVI. Aim To describe the association between pre-procedural kidney function and long-term outcomes in TAVI patients. Methods We used Danish nationwide registries to identify patients with aortic stenosis undergoing TAVI between 2015 and end 2022. Patients were categorized by baseline eGFR: ≥60, 30-59, and <30 mL/min/1.73m2 or recent dialysis. We examined one-year all-cause mortality and hospitalization burden after TAVI and estimated relative risks using multivariable cox and logistic regression. Results We included 3,888 (60.7%) patients with eGFR ≥60 (58.4% male; median age, 80 years), 2,185 (34.1%) with eGFR 30–59 (55.5% male; median age, 83), and 336 (5,2%) with eGFR <30 or recent dialysis (58.0% male; median age, 81). One-year all-cause mortality was 5.6% for eGFR ≥60, 9.1% for eGFR 30-59, and 19.6% for eGFR <30 or dialysis. Adjusted hazard ratio was significantly higher for eGFR 30–60 (aHR, 1.45; 95%CI, 1.19–1.78, p=0.0003) and eGFR <30 or dialysis (aHR, 3.07; 95%CI, 2.32–4.08, p<0.0001) than eGFR ≥60. Cumulative rehospitalization >14 days after TAVI was most frequent among patients with eGFR <30 or dialysis (18.4%). Conclusion We observed a stepwise association between pre-TAVI kidney function and post-TAVI one-year mortality as well as hospitalization burden. Kidney impairment potentially has substantial prognostic impact and should be incorporated into lifetime TAVI patient management.
No takes yet. Share an insight, caveat, or question.
Meibom et al. (2026) conducted a cohort in Aortic stenosis undergoing TAVI (n=6,409). Severe kidney impairment (eGFR <30 mL/min/1.73m2 or dialysis) vs. Normal or mildly impaired kidney function (eGFR ≥60 mL/min/1.73m2) was evaluated on One-year all-cause mortality (aHR 3.07, 95% CI 2.32-4.08, p=<0.0001). Severe kidney impairment (eGFR <30 or dialysis) before TAVI was associated with higher one-year all-cause mortality compared to eGFR ≥60 (aHR 3.07; 95% CI 2.32-4.08; P<0.0001).